title: Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes.
abstract: A significant proportion of relatives of patients with insulin-dependent (type I) diabetes with high titers of cytoplasmic islet cell autoantibodies (ICAs) do not progress to overt diabetes with up to 8 yr of follow-up. This may reflect that follow-up of such relatives has not been long enough to observe diabetes, that despite expression of identical ICAs, some relatives will not progress to diabetes; or that there is heterogeneity in what is identified as ICA. We identified a subset of ICA that was restricted in its species (not reacting with mouse islets) and cell-type reactivity within islets (beta-cell specific). Only one of eight relatives whose sera had the restricted pattern of reactivity progressed to overt diabetes, and on sequential evaluation, all but the one relative who progressed to diabetes have maintained normal first-phase insulin secretion to intravenous glucose. In contrast, by life-table analysis, 70% of relatives expressing nonrestricted ICA became diabetic within 5 yr of follow-up (1 of 8 vs. 16 of 25 diabetic at last follow-up, P less than 0.02). Moreover, preliminary data suggest a significant association of the human leukocyte antigen DQB1*0602 allele of DR2 haplotypes with the restricted ICA pattern (4 of 5 DQB1*0602 restricted vs. 0 nonrestricted ICA, P = 0.006). We propose that expression of a genetically determined restricted ICA pattern confers a markedly lower risk for progression to diabetes.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Joslin Diabetes Center, Brigham and Womens Hospital, Boston, MA 02115.
authors.forename: R
authors.initials: R
authors.lastname: Gianani
authors.forename: A
authors.initials: A
authors.lastname: Pugliese
authors.forename: S
authors.initials: S
authors.lastname: Bonner-Weir
authors.forename: A J
authors.initials: AJ
authors.lastname: Shiffrin
authors.forename: J S
authors.initials: JS
authors.lastname: Soeldner
authors.forename: H
authors.initials: H
authors.lastname: Erlich
authors.forename: Z
authors.initials: Z
authors.lastname: Awdeh
authors.forename: C A
authors.initials: CA
authors.lastname: Alper
authors.forename: R A
authors.initials: RA
authors.lastname: Jackson
authors.forename: G S
authors.initials: GS
authors.lastname: Eisenbarth
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal; D001323:Autoantibodies / Q000032:analysis*; D003593:Cytoplasm / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics* / Q000276:immunology*; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006801:Humans; D007124:Immunoenzyme Techniques; D007075:Immunoglobulin M; D007515:Islets of Langerhans / Q000276:immunology*; D051379:Mice; D011236:Prediabetic State / Q000175:diagnosis / Q000235:genetics / Q000276:immunology; D011379:Prognosis; D011446:Prospective Studies; D051381:Rats
chemical_list: D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007075:Immunoglobulin M; C024211:islet cell antibody